It may be that VTAMA reduces TRM cells in the skin, which are the T-cells responsible for relapse. There's is an ongoing clinical trial right now called KNOCKOUT [1] that gives patients a "megadose" of Skyrizi, an IL-23 inhibitor that has, like VTAMA, been shown to reduce TRM cells. The idea is that a single huge dose could effectively cure psoriasis, or at least suppress it for a very long time. The results so far show that 83% of patients achieved complete clearance after six months, which was sustained throughout the trial period. I'm confident it will be a game changer. Here [2] is an interview with the main researcher.
Among new psoriasis drugs, there is also Zoryve, a PDE4 inhibitor (same mechanism as Otezla) as a cream or foam, which has a different mechanism of action.
[1] https://www.hcplive.com/view/risankizumab-dose-clears-psoria...
[2] https://www.hcplive.com/view/rizankizumab-knockout-study-and...